Results 251 to 260 of about 41,661 (291)
Some of the next articles are maybe not open access.
2020
Androgen deprivation therapy (ADT) has been the standard of care for treating advanced prostate cancer for many decades. Prostate cancer cells are generally androgen-dependent, and most patients with advanced disease will respond to ADT in some form or another. Androgen deprivation therapy is utilized in the suppression of testosterone production.
Charlene Reyes +2 more
openaire +2 more sources
Androgen deprivation therapy (ADT) has been the standard of care for treating advanced prostate cancer for many decades. Prostate cancer cells are generally androgen-dependent, and most patients with advanced disease will respond to ADT in some form or another. Androgen deprivation therapy is utilized in the suppression of testosterone production.
Charlene Reyes +2 more
openaire +2 more sources
Head and Neck, 2016 Background Androgen deprivation therapy has some clinical activity in selected salivary gland cancer histotypes, with androgen receptor expression.
Laura D Locati +2 more
exaly +2 more sources
Androgen deprivation therapy and cardiovascular disease
Urologic Oncology: Seminars and Original Investigations, 2020Prostate cancer (PCa) is the most common cancer among men. Advances in early detection and successful treatments have improved cancer-specific survival. With prolonged survival, PCa patients now suffer from the effects of aging and are at increasing risk for the development of cardiovascular (CV) risk factors and CV disease.
Chiara, Melloni, Matthew T, Roe
openaire +2 more sources
Indications and Practice With Androgen Deprivation Therapy
Urology, 2011The Cancer of the Prostate Strategic Urological Research Endeavor (CaPSURE) is an ongoing longitudinal observational study of current trends in prostate cancer staging and treatment across a spectrum of different treatment facilities in the United States.
Judd W, Moul +3 more
openaire +2 more sources
Androgen Deprivation Therapy and Competing Risks
JAMA, 2011among patients receiving ADT vs control was 11.0% (95% CI, 8.3%-14.5%) vs 11.2% (95% CI, 8.3%-15.0%), respectively, and the corresponding relative risk (RR) was not significant (0.93; 95% CI, 0.79-1.10; P=.41). The duration of ADT (long duration [3 years] vs short duration [6 months]) was not associated with increased cardiovascular death. An important
William K, Kelly, Leonard G, Gomella
openaire +2 more sources
Traditional Approaches to Androgen Deprivation Therapy
Urology, 2011For most of the past 25 years, 1 of the favored approaches to treating prostate cancer has been the suppression of circulating testosterone with luteinizing hormone-releasing hormone (LHRH) agonists. LHRH agonists produce a downregulation of LHRH receptors and an uncoupling of the LHRH signal transduction mechanism.
Judd W, Moul +4 more
openaire +2 more sources
Embodied masculinity and androgen deprivation therapy
Sociology of Health and Illness, 2006This paper describes the findings from an ethnographic study of 16 Anglo-Australian men treated with androgen deprivation therapy (ADT) for advanced prostate cancer. Utilising a social constructionist gendered analysis, participants' experiences, particularly in relation to embodied masculinity, are described in the context of reduced testosterone that
openaire +2 more sources
Complications of Androgen-Deprivation Therapy for Prostate Cancer
Clinical Prostate Cancer, 2003Androgen deprivation as a form of treatment for prostate cancer has been used for decades. Within the last decade, however, there has been a significant increase in its use. Therefore, it is incumbent upon the physician to be familiar with the side effects associated with this treatment.Some of the side effects such as osteoporosis, changes in lipid ...
Jeffrey M, Holzbeierlein +2 more
openaire +3 more sources
2010
Androgen deprivation therapy (ADT) is the upfront systemic therapy for advanced prostate cancer. ADT is administered medically or through surgical castration, and it suppresses serum testosterone levels. Furthermore, ADT may be given alone or in combination with an androgen receptor antagonist.
openaire +1 more source
Androgen deprivation therapy (ADT) is the upfront systemic therapy for advanced prostate cancer. ADT is administered medically or through surgical castration, and it suppresses serum testosterone levels. Furthermore, ADT may be given alone or in combination with an androgen receptor antagonist.
openaire +1 more source
Complications of androgen deprivation therapy in prostate cancer
Current Opinion in Urology, 2009To review the current data on adverse effects of androgen deprivation therapy for prostate cancer and to discuss some considerations when choosing therapy and managing side-effects.Despite the existing data supporting the use of androgen deprivation therapy in prostate cancer patients, several questions regarding timing, survival benefit and impact in ...
Anita, Schwandt, Jorge A, Garcia
openaire +2 more sources